IL280013B1 - Anti-il36r antibodies - Google Patents
Anti-il36r antibodiesInfo
- Publication number
- IL280013B1 IL280013B1 IL280013A IL28001321A IL280013B1 IL 280013 B1 IL280013 B1 IL 280013B1 IL 280013 A IL280013 A IL 280013A IL 28001321 A IL28001321 A IL 28001321A IL 280013 B1 IL280013 B1 IL 280013B1
- Authority
- IL
- Israel
- Prior art keywords
- seq
- cdr
- amino acid
- acid sequence
- set forth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862698482P | 2018-07-16 | 2018-07-16 | |
| US201962846989P | 2019-05-13 | 2019-05-13 | |
| US201962866028P | 2019-06-25 | 2019-06-25 | |
| PCT/US2019/041952 WO2020018503A2 (en) | 2018-07-16 | 2019-07-16 | Anti-il36r antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL280013A IL280013A (en) | 2021-03-01 |
| IL280013B1 true IL280013B1 (en) | 2026-01-01 |
Family
ID=67480435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL280013A IL280013B1 (en) | 2018-07-16 | 2021-01-07 | Anti-il36r antibodies |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11267893B2 (https=) |
| EP (1) | EP3823989A2 (https=) |
| JP (1) | JP7386224B2 (https=) |
| KR (1) | KR102895164B1 (https=) |
| CN (1) | CN112513091B (https=) |
| AU (1) | AU2019306217B2 (https=) |
| BR (1) | BR112020027015A2 (https=) |
| CA (1) | CA3103531A1 (https=) |
| IL (1) | IL280013B1 (https=) |
| MX (2) | MX2021000566A (https=) |
| PH (1) | PH12020552178A1 (https=) |
| SG (1) | SG11202012360YA (https=) |
| WO (1) | WO2020018503A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016168542A1 (en) | 2015-04-15 | 2016-10-20 | Anaptysbio, Inc. | Antibodies directed against interleukin 36 receptor (il-36r) |
| CA3093692A1 (en) | 2018-03-14 | 2019-09-19 | Boehringer Ingelheim International Gmbh | Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis |
| MX2021000566A (es) | 2018-07-16 | 2021-06-23 | Regeneron Pharma | Anticuerpos anti-il36r. |
| EP4182022A1 (en) | 2020-07-17 | 2023-05-24 | Boehringer Ingelheim International GmbH | Anti-il-36r antibodies for the treatment of neutrophilic dermatoses |
| JP2023536851A (ja) | 2020-07-30 | 2023-08-30 | アナプティスバイオ インコーポレイティッド | 魚鱗癬のための抗インターロイキン３６受容体（ｉｌ－３６ｒ）療法 |
| WO2022026829A1 (en) | 2020-07-30 | 2022-02-03 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity |
| CN112094349B (zh) * | 2020-11-04 | 2021-02-09 | 上海华奥泰生物药业股份有限公司 | 靶向于白介素36r的抗体及其制备方法和应用 |
| EP4289863A4 (en) * | 2020-12-17 | 2025-04-09 | Shanghai Huaota Biopharmaceutical Co., Ltd. | BISPECIFIC ANTIBODY AGAINST IL-17A AND IL-36R AND USE THEREOF |
| WO2022150642A1 (en) | 2021-01-08 | 2022-07-14 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa |
| WO2022150644A1 (en) | 2021-01-08 | 2022-07-14 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for acne |
| WO2022166977A1 (zh) * | 2021-02-08 | 2022-08-11 | 上海普铭生物科技有限公司 | 抗人il-36r抗体及其应用 |
| CA3209006A1 (en) * | 2021-03-04 | 2022-09-09 | Boehringer Ingelheim International Gmbh | Methods for the treatment of gpp |
| WO2022192531A2 (en) | 2021-03-12 | 2022-09-15 | Boehringer Ingelheim International Gmbh | Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis |
| CN117480183A (zh) * | 2021-06-18 | 2024-01-30 | 正大天晴药业集团股份有限公司 | 抗il-36r抗体及其用途 |
| EP4370550A1 (en) * | 2021-07-12 | 2024-05-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of il-36 inhibitors for the treatment of netherton syndrome |
| US20250120374A1 (en) * | 2021-10-25 | 2025-04-17 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric genes |
| TW202323293A (zh) * | 2021-10-29 | 2023-06-16 | 新加坡商創響私人有限公司 | 新型抗ｉｌ－３６ｒ抗體 |
| CN115724975A (zh) | 2022-10-20 | 2023-03-03 | 江苏荃信生物医药股份有限公司 | 抗人白介素36受体单克隆抗体及其应用 |
| CN116574189A (zh) * | 2023-01-30 | 2023-08-11 | 北京智仁美博生物科技有限公司 | 针对人il-36r和/或人il-1r3的多种抗体及其用途 |
| JP2026506716A (ja) | 2023-02-21 | 2026-02-25 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | Ｉｌ－３６ｒ結合タンパク質及びその医薬的使用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013074569A1 (en) * | 2011-11-16 | 2013-05-23 | Boehringer Ingelheim International Gmbh | Anti il-36r antibodies |
| WO2016168542A1 (en) * | 2015-04-15 | 2016-10-20 | Anaptysbio, Inc. | Antibodies directed against interleukin 36 receptor (il-36r) |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5693489A (en) | 1984-03-30 | 1997-12-02 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US6239268B1 (en) | 1994-09-09 | 2001-05-29 | Neurocrine Biosciences, Inc. | Interleukin-1 type 3 receptors |
| JPH10508743A (ja) | 1994-09-09 | 1998-09-02 | ニューロクライン バイオサイエンシーズ， インコーポレイテッド | インターロイキン−１ タイプ３レセプター |
| US6326472B1 (en) | 1997-10-15 | 2001-12-04 | Schering Corporation | Human receptor proteins; related reagents and methods |
| WO1999019480A2 (en) | 1997-10-15 | 1999-04-22 | Schering Corporation | Human receptor proteins; related reagents and methods |
| US20060003323A1 (en) | 2000-03-01 | 2006-01-05 | John Alsobrook | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| US6900016B1 (en) | 2000-09-08 | 2005-05-31 | Applera Corporation | Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20030170630A1 (en) | 2000-12-21 | 2003-09-11 | Alsobrook John P. | Proteins and nucleic acids encoding same |
| WO2005100604A2 (en) | 2004-04-01 | 2005-10-27 | Sequenom, Inc. | Methods for identifying risk of osteoarthritis and treatments thereof |
| WO2005108415A2 (en) | 2004-04-30 | 2005-11-17 | Biogen Idec Ma Inc. | Membrane associated molecules |
| CA2625403A1 (en) | 2005-10-17 | 2007-04-26 | Institute For System Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| WO2014144666A2 (en) * | 2013-03-15 | 2014-09-18 | The University Of Chicago | Methods and compositions related to t-cell activity |
| JP2020512344A (ja) | 2017-03-27 | 2020-04-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗ｉｌ−３６ｒ抗体併用治療 |
| AU2019234478A1 (en) | 2018-03-14 | 2020-08-20 | Boehringer Ingelheim International Gmbh | Use of anti-IL36R antibodies for treatment of inflammatory bowel disease |
| CA3093692A1 (en) | 2018-03-14 | 2019-09-19 | Boehringer Ingelheim International Gmbh | Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis |
| MX2021000566A (es) | 2018-07-16 | 2021-06-23 | Regeneron Pharma | Anticuerpos anti-il36r. |
| IL278267B2 (en) | 2018-07-16 | 2025-02-01 | Regeneron Pharma | Non-human animal models of DITRA disease and their uses |
-
2019
- 2019-07-16 MX MX2021000566A patent/MX2021000566A/es unknown
- 2019-07-16 SG SG11202012360YA patent/SG11202012360YA/en unknown
- 2019-07-16 CN CN201980050334.0A patent/CN112513091B/zh active Active
- 2019-07-16 US US16/512,886 patent/US11267893B2/en active Active
- 2019-07-16 JP JP2021502424A patent/JP7386224B2/ja active Active
- 2019-07-16 BR BR112020027015-6A patent/BR112020027015A2/pt unknown
- 2019-07-16 CA CA3103531A patent/CA3103531A1/en active Pending
- 2019-07-16 KR KR1020217002970A patent/KR102895164B1/ko active Active
- 2019-07-16 AU AU2019306217A patent/AU2019306217B2/en active Active
- 2019-07-16 EP EP19746372.2A patent/EP3823989A2/en active Pending
- 2019-07-16 WO PCT/US2019/041952 patent/WO2020018503A2/en not_active Ceased
-
2020
- 2020-12-15 PH PH12020552178A patent/PH12020552178A1/en unknown
-
2021
- 2021-01-07 IL IL280013A patent/IL280013B1/en unknown
- 2021-01-14 MX MX2025007735A patent/MX2025007735A/es unknown
-
2022
- 2022-02-01 US US17/590,319 patent/US12060428B2/en active Active
-
2024
- 2024-07-01 US US18/760,617 patent/US20250011442A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013074569A1 (en) * | 2011-11-16 | 2013-05-23 | Boehringer Ingelheim International Gmbh | Anti il-36r antibodies |
| WO2016168542A1 (en) * | 2015-04-15 | 2016-10-20 | Anaptysbio, Inc. | Antibodies directed against interleukin 36 receptor (il-36r) |
Non-Patent Citations (2)
| Title |
|---|
| IRINA KHANSKAYA ET AL,, A PHASE 1 STUDY OF ANB019, AN ANTI-IL-36 RECEPTOR MONOCLONAL ANTIBODY, IN HEALTHY VOLUNTEERS, 1 May 2018 (2018-05-01) * |
| RAJKUMAR GANESAN ET AL,, GENERATION AND FUNCTIONAL CHARACTERIZATION OF ANTI-HUMAN AND ANTI-MOUSE IL-36R ANTAGONIST MONOCLONAL ANTIBODIES, 3 October 2017 (2017-10-03) * |
Also Published As
| Publication number | Publication date |
|---|---|
| PH12020552178A1 (en) | 2021-06-28 |
| SG11202012360YA (en) | 2021-01-28 |
| CA3103531A1 (en) | 2020-01-23 |
| WO2020018503A2 (en) | 2020-01-23 |
| AU2019306217B2 (en) | 2024-01-25 |
| US20220162326A1 (en) | 2022-05-26 |
| CN112513091B (zh) | 2024-08-27 |
| WO2020018503A3 (en) | 2020-02-20 |
| KR20210032401A (ko) | 2021-03-24 |
| JP2021530229A (ja) | 2021-11-11 |
| MX2021000566A (es) | 2021-06-23 |
| JP7386224B2 (ja) | 2023-11-24 |
| US12060428B2 (en) | 2024-08-13 |
| US20250011442A1 (en) | 2025-01-09 |
| KR102895164B1 (ko) | 2025-12-04 |
| IL280013A (en) | 2021-03-01 |
| US11267893B2 (en) | 2022-03-08 |
| EP3823989A2 (en) | 2021-05-26 |
| MX2025007735A (es) | 2025-08-01 |
| CN112513091A (zh) | 2021-03-16 |
| BR112020027015A2 (pt) | 2021-04-06 |
| NZ771227A (en) | 2024-04-26 |
| AU2019306217A1 (en) | 2021-01-14 |
| US20200017592A1 (en) | 2020-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12060428B2 (en) | Anti-IL36R antibodies | |
| AU2020214812B2 (en) | Anti-IL2 receptor gamma antigen-binding proteins | |
| EP1776142B3 (en) | Il-17 antagonistic antibodies | |
| JP2021530229A5 (https=) | ||
| KR20120102623A (ko) | 조작된 항－ｔｓｌｐ 항체 | |
| CN101986784A (zh) | 基因工程tslpr抗体 | |
| US20190040156A1 (en) | ANTI-TNF- / ANTI-IL-23 IgG BISPECIFIC ANTIBODIES | |
| KR20220033504A (ko) | 흉선 기질 림프포이에틴(tslp)-수용체 신호전달을 방해하는 제제 | |
| CA3194457A1 (en) | Caninized antibodies to canine interleukin-31 receptor alpha | |
| JP7307720B2 (ja) | Ｉｌ－５抗体、その抗原結合フラグメント、およびそれらの医薬適用 | |
| KR20210084473A (ko) | 항인간 Fn14 항체 | |
| US20230053131A1 (en) | Antibodies to canine interleukin-4 receptor alpha | |
| AU2019236822A1 (en) | GIPR antibody and GLP-1 fusion protein thereof, and pharmaceutical composition and application thereof | |
| JP2025500806A (ja) | ヒトｎｇｆに対するイヌ化抗体 | |
| EA049652B1 (ru) | Антитела к il36r | |
| US20250197514A1 (en) | ANTIBODIES AND IgG FUSION PROTEINS WITH AN EXTENDED HALF-LIFE | |
| US20240158515A1 (en) | Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof | |
| RU2575039C2 (ru) | Сконструированное антитело против tslp | |
| HK40110084A (zh) | 具有延长的半衰期的抗体和igg融合蛋白 |